Andexanet alfa for oral fxa inhibitor-associated major acute intracerebral hemorrhage: insights into clinically relevant thromboembolic events from the ANNEXA-I study
Andexanet alfa para hemorragia intracerebral aguda grave associada a inibidores orais do fxa: percepções sobre eventos tromboembólicos clinicamente relevantes a partir do estudo ANNEXA-I
Mateo Porres-Aguilar; Luis Antonio Meillon-Garcia; João Carlos de Campos Guerra
References
1 Russo V, Attena E, Di Maio M, et al. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. J Thromb Thrombolysis. 2020;49(1):42-53.
2 Haas S, Ageno W, Weitz JI, et al. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. J Thromb Haemost. 2019;17(10):1694-706.
3 Seiffge DJ, Paciaroni M, Wilson D, et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol. 2019;85(6):823-34.
4 van Es N, De Caterina R, Weitz JI. Reversal agents for current and forthcoming direct oral anticoagulants. Eur Heart J. 2023;44(20):1795-806.
5 Sarode R, Welsby IJ, Hoffman M. Clinical relevance of preclinical and clinical studies of four-factor prothrombin complex concentrate for treatment of bleeding related to direct oral anticoagulants. Ann Emerg Med. 2023;82(3):341-61.
6 Siddiqui F, Tafur A, Ramacciotti LS, et al. Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values. Clin Appl Thromb Hemost. 2019;25:1076029619863493.
7 Milling TJ Jr, Middeldorp S, Xu L, et al. Final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Circulation. 2023;147(13):1026-38.
8 Connolly SJ, Sharma M, Cohen AT, et al. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med. 2024;390(19):1745-55.
9 Levy JH, Shaw JR, Castellucci LA, et al. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2024;22(10):2889-99. http://doi.org/10.1016/j.jtha.2024.07.009. PMid:39029742.
10 Prakash S, Mares AC, Porres-Aguilar M, Mukherjee D, Barnes GD. Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: a narrative review. Vasc Med. 2024;29(1):85-92.
11 Porres-Aguilar M. ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism. J Vasc Bras. 2023;22:e20230051.
12 Salomon O, Gailani D. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors. J Thromb Haemost. 2022;20(1):32-8.
Submitted date:
09/03/2024
Accepted date:
09/08/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email